methamphetamine hydrochloride
GPTKB entity
Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
recreational drug |
| gptkbp:administeredBy |
oral
intravenous intranasal |
| gptkbp:ATCCode |
N06BA03
|
| gptkbp:CASNumber |
51-57-0
|
| gptkbp:controlled_substance_schedule |
gptkb:Schedule_II_(US)
|
| gptkbp:form |
C10H15N·HCl
|
| gptkbp:has_trade_name |
gptkb:Desoxyn
|
| gptkbp:hasSMILES |
CNC(C)CC1=CC=CC=C1.Cl
|
| gptkbp:hasUNII |
7003N435QS
|
| https://www.w3.org/2000/01/rdf-schema#label |
methamphetamine hydrochloride
|
| gptkbp:is_salt_form_of |
amphetamine
|
| gptkbp:IUPACName |
N-methyl-1-phenylpropan-2-amine hydrochloride
|
| gptkbp:KEGGID |
D08125
|
| gptkbp:legalStatus |
Prescription only (US)
|
| gptkbp:meltingPoint |
170-175 °C
|
| gptkbp:molecularWeight |
185.7 g/mol
|
| gptkbp:PubChem_CID |
4092
CHEMBL1201207 DB01577 3949 |
| gptkbp:sideEffect |
addiction
anxiety paranoia insomnia |
| gptkbp:usedFor |
recreational drug
stimulant treatment for ADHD treatment for obesity |
| gptkbp:bfsParent |
gptkb:Desoxyn
|
| gptkbp:bfsLayer |
6
|